Pāriet uz galveno navigāciju Pāriet uz meklēšanu Pāriet uz galveno saturu

Hybrid, infection- and vaccination-induced protection against laboratory- confirmed SARS-CoV-2 infection in a European multi-centre prospective cohort of healthcare workers, 2021–2024

  • VEBIS HCW VE study group
  • Epiconcept
  • European Centre for Disease Prevention and Control
  • Croatian National Institute of Public Health
  • University of Tartu
  • Department of Genitourinary Medicine and Infectious Diseases (GUIDe)
  • Trinity College Dublin
  • University of Galway
  • Azienda Ospedaliera San Gerardo Monza
  • University of Milan
  • Catholic University of the Sacred Heart
  • Fondazione Policlinico Universitario “A. Gemelli” IRCCS
  • Paula Stradina Clinical University Hospital
  • Children's Clinical University Hospital
  • National Medical Institute of the Ministry of the Interior and Administration
  • Instituto Nacional de Saúde Doutor Ricardo Jorge
  • Victor Babes National Institute
  • Carol Davila University of Medicine and Pharmacy
  • National Institute for Mother and Child Care Alessandrescu Rusescu
  • SJD Barcelona Children's Hospital
  • UIC Barcelona
  • Ciber of Epidemiology and Public Health CIBERESP
  • Miguel Servet University Hospital (IIS Aragón)
  • Viljandi Hospital
  • Cantacuzino National Military-Medical Institute for Research and Development

Zinātniskās darbības rezultāts: Devums žurnālamZinātniskais raksts (žurnālā)koleģiāli recenzēts

Kopsavilkums

Background: Healthcare workers (HCWs) face high occupational exposure to SARS-CoV-2 and are a priority group for vaccination. Both natural infection and vaccination—individually or combined as hybrid immunity—confer protection against SARS-CoV-2 infection. This study aimed to evaluate the protection conferred by hybrid, infection-induced, and booster vaccine-induced immunity against laboratory-confirmed SARS-CoV-2 infections in HCWs during the circulation of three pandemic and one post-pandemic Omicron sublineages. Methods: We conducted a prospective cohort study of HCWs from 18 hospitals across nine European countries. Participants underwent RT-PCR testing at enrolment and during weekly or fortnightly follow-ups. The study period was divided based on dominant Omicron sublineage circulation: BA.1/2 (Dec 16, 2021–Jun 1, 2022), BA.4/5/BQ.1 (Jun 2–Dec 31, 2022), BA.2/XBB (Jan 1–May 2, 2023), and post-pandemic XBB.1.5/BA.2.86 (Sep 1, 2023–May 21, 2024). Participants were classified into four groups: hybrid (prior infection and recent booster vaccination 7–179 days), infection-induced (prior infection, no recent vaccination), vaccine-induced immunity (recent booster vaccination, no prior infection), and a reference group (no prior infection, no recent booster vaccination). Adjusted hazard ratios (aHRs) for infection were estimated using Cox regression, adjusting for hospital, age, sex, chronic condition, and patient-facing role. Results: A total of 3 133 HCWs were included: 2572 (82%) female, 1734 (55%) aged 40–59, and 563 (29%) with ≥ 1 chronic condition. Hybrid immunity showed significant protection during BA.1/2 (aHR = 0.37, 95%CI 0.21–0.63), BA.4/5/BQ.1 (aHR = 0.36, 95%CI 0.22–0.58), and XBB.1.5/BA.2.86 (aHR = 0.53, 95%CI 0.37–0.74) periods. Infection-induced immunity was protective across all periods, most during BA.1/2 (aHR = 0.26, 95%CI 0.12–0.53), and least during BA.2/XBB (aHR = 0.66, 95%CI 0.36–1.22). Vaccine-induced immunity alone offered limited protection during BA.1/2 (aHR = 0.72, 95%CI 0.49–1.06) and BA.4/5/BQ.1 (aHR = 0.77, 95%CI 0.50–1.19), with wide confidence intervals suggesting low statistical significance. Conclusions: Hybrid and infection-induced immunity groups were more protected against infection caused by earlier Omicron sub-lineages and more protected than vaccination alone, which had no significant protective effect. These findings highlight the need for adaptive public health strategies, including timely vaccine updates and understanding of prior SARS-CoV-2 infection to inform COVID-19 vaccination policies for HCWs in the post-pandemic era.

OriģinālvalodaAngļu
Raksta numurs697
ŽurnālsBMC Medicine
Sējums23
Izdevuma numurs1
DOIs
Publikācijas statussPublicēts - dec. 2025
Ārēji publicēts

ANO IAM

Šis izpildes rezultāts palīdz sasniegt šādus ANO ilgtspējīgas attīstības mērķus (IAM)

  1. 3. IAM — Laba Veselība un Labbūtība
    3. IAM — Laba Veselība un Labbūtība

Nospiedums

Uzziniet vairāk par pētniecības tēmām “Hybrid, infection- and vaccination-induced protection against laboratory- confirmed SARS-CoV-2 infection in a European multi-centre prospective cohort of healthcare workers, 2021–2024”. Kopā tie veido unikālu nospiedumu.

Citēt šo